Dosing & Safety
Attruby is conveniently packaged and has a safety profile demonstrated in
patients with ATTR-CM
Actor portrayals.
Attruby tablets are
available in a convenient
1-month supply1
No concomitant medications or supplements required per label
Not actual size.
Make Attruby dosing a part of your patient’s daily routine
1 monthly carton includes
4 weekly blister packs1
The recommended dosage is 712 mg
(two 356-mg tablets) taken orally twice a day, with or without food.1
Tablets should be swallowed whole. Do not cut, crush, or chew.1
Of patients with ATTR-CM,
9 out of 10 are already taking medications multiple times a day2*
*Based on descriptive analyses of chronic oral medication use in patients from ATTRibute-CM (N=632) and real-world data of patients with ATTR-CM (N=4725) from Optum Clinformatics Data Mart.
ATTR-CM=transthyretin amyloid cardiomyopathy.
References: 1. Attruby. Prescribing information. BridgeBio Pharma, Inc.; 2024. 2. Dasgupta N, Poulsen SH, Emdin M, et al. Contemporary oral medication use and frequency in patients with transthyretin amyloid cardiomyopathy. Am J Cardiovasc Drugs. Published online August 1, 2025. doi:10.1007/s40256-025-00752-x
Indication and Important safety information
INDICATION
Attruby® (acoramidis) is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
IMPORTANT SAFETY INFORMATION
Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were
reported in patients treated with Attruby versus placebo,
respectively. The majority of these adverse reactions were mild and
resolved without drug discontinuation.
Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).
Laboratory Tests
Mean increase in serum creatinine of 0.2 and 0.0 mg/dL and a mean
decrease in eGFR of 8.2 and 0.7 mL/min/1.73 m2 was
observed in the
adults with ATTR-CM treated with Attruby versus placebo,
respectively, at Day 28 and then stabilized. These changes were
reversible after treatment discontinuation.
Use in Specific Populations
Pregnancy & Lactation: There are no data on the use of Attruby in pregnant women. Animal data have not shown developmental risk associated with the use of Attruby in pregnancy. There are no available data on the presence of Attruby in either human or animal milk or the effects of the drug on the breastfed infant or maternal milk production.
Please see Full Prescribing Information including Patient Information.
INDICATION AND IMPORTANT
SAFETY INFORMATION
INDICATION
Attruby® (acoramidis) is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
IMPORTANT SAFETY INFORMATION
Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were
reported in patients treated with Attruby versus placebo,
respectively. The majority of these adverse reactions were mild and
resolved without drug discontinuation.
Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).
Laboratory Tests
Mean increase in serum creatinine of 0.2 and 0.0 mg/dL and a mean
decrease in eGFR of 8.2 and 0.7 mL/min/1.73 m2 was
observed in the
adults with ATTR-CM treated with Attruby versus placebo,
respectively, at Day 28 and then stabilized. These changes were
reversible after treatment discontinuation.
Use in Specific Populations
Pregnancy & Lactation: There are no data on the use of Attruby in pregnant women. Animal data have not shown developmental risk associated with the use of Attruby in pregnancy. There are no available data on the presence of Attruby in either human or animal milk or the effects of the drug on the breastfed infant or maternal milk production.
Please see Full Prescribing Information including Patient Information.